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Kidney Transplant Recipients with Cutaneous
Squamous Cell Carcinoma Have an Increased
Risk of Internal Malignancy
Hermina C. Wisgerhof1, Ron Wolterbeek2, Johan W. de Fijter3, Rein Willemze1 and Jan N. Bouwes Bavinck1
This study aimed to investigate whether the occurrence of cutaneous squamous cell carcinomas (SCCs) is
associated with an increased risk of internal malignancies (IMs) in kidney transplant recipients (KTRs). In a
cohort study, all patients receiving kidney transplantation in Leiden, the Netherlands, between 1966 and 2006
were followed up. All malignancies that had developed between 1966 and 2007 were recorded. Time-dependent
Cox regression analyses were used to calculate the association between the development of cutaneous SCCs
and IMs. The incidence of IMs in the KTRs after transplantation was also compared with the general Dutch
population by calculating standardized morbidity ratios (SMRs) and was matched for age, sex, and time period
in which the malignancy had occurred. Among 1,800 KTRs, 176 (9.8%) developed cutaneous SCCs and 142 (7.9%)
developed IMs after transplantation. In patients with prior cutaneous SCCs, the adjusted risk to develop IMs
was 3.0 (1.9; 4.7). In KTRs without cutaneous SCCs, the risk of IM compared with the general population was
hardly increased. KTRs with cutaneous SCCs have an increased risk to develop IMs, and this information can be
used to identify KTRs who are at an increased risk for IMs.
Journal of Investigative Dermatology (2012) 132, 2176–2183; doi:10.1038/jid.2012.132; published online 26 April 2012
INTRODUCTION
Kidney transplant recipients (KTRs), as well as other organ
transplant recipients, have a 2- to 6-fold increased risk of
malignancy compared with the general population (Hartevelt
et al., 1990; London et al., 1995; Adami et al., 2003; Euvrard
et al., 2003; Vajdic et al., 2006; Grulich et al., 2007;
Villeneuve et al., 2007; Alam et al., 2011; Wisgerhof et al.,
2011) and many KTRs develop multiple malignancies
(Euvrard et al., 2006; Wisgerhof et al., 2010). In the
Netherlands, the standardized morbidity ratio (SMR) for
internal malignancies (IMs) in KTRs compared with the age-
and sex-matched general population was 1.6 (95% con-
fidence interval, 1.4; 1.9), and for cutaneous squamous cell
carcinoma (SCC) the SMR was 39.6 (34.2; 45.9; Wisgerhof
et al., 2011).
The risk of IMs after the occurrence of cutaneous SCCs has
been studied in the general population. Some studies showed
that patients with a cutaneous SCCs have a 2-fold increased
risk of IMs (Levi et al., 1997; Karagas et al., 1998; Wassberg
et al., 1999; Hjalgrim et al., 2000; Hu et al., 2005; Chen
et al., 2008), but other studies showed no increased risk of
IMs, or even a slightly decreased risk, after the occurrence
of cutaneous SCCs (Levi et al., 1997; de Vries et al., 2007;
Grant, 2007; Tuohimaa et al., 2007; Soerjomataram et al.,
2008; Cantwell et al., 2009). As far as we know, no previous
studies have investigated the association between cutaneous
SCCs and IMs in KTRs.
The aims of this study were to investigate the risk of IMs
after the occurrence of cutaneous SCCs in KTRs and to
determine whether KTRs who develop cutaneous SCCs can
be used to identify patients who are at an increased risk
for IMs.
RESULTS
Baseline characteristics of the KTRs
Between March 1966 and January 2006, 1906 patients
received their first kidney transplant in Leiden (Wisgerhof
et al., 2011). Figure 1 shows that 106 patients were excluded
because of different reasons. Of the remaining 1,800 patients,
176 (9.8%) had developed one or more cutaneous SCCs and
142 (7.9%) had developed one or more IMs, whereas 1,521
(84.5%) KTRs did not develop any type of cancer. The
baseline characteristics of the patients without and with
cancer are provided in Table 1. This cohort may differ from
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other centers, because of the large number of KTRs who were
transplanted before 1986 and the high number of KTRs on
maintenance therapy with azathioprine (Aza) in any combi-
nation. The median age at transplantation of the 1,800 KTRs
together was 43 years (ranging from 4 to 77 years), with a
median follow-up of 11 years (ranging from 0.1 to 40 years);
62% were male patients, which is caused by a predominance
of kidney problems in the male population.
Prognostic factors for cancer
Non-adjusted and adjusted hazard ratios to develop cuta-
neous SCC or IM are presented in Table 2. Increased age at
transplantation was, as could be expected, a statistically
significant prognostic factor for both cutaneous SCCs and
IMs. Male sex was a significant risk factor for cutaneous
SCCs but not for IMs. KTRs immunosuppressed with Aza
had the highest risk to develop both cutaneous SCCs and
IMs, but for this association there was some confounding by
the time period of transplantation. This is illustrated by the
hazard ratio of 1.7 for developing IMs in KTRs who were
immunosuppressed with cyclosporine A or tacrolimus
compared with Aza, which reverted to 0.83 after adjustment
for time period of transplantation (Table 2).
The time period of transplantation had an important
impact on the risk of cutaneous SCCs but not on the risk of
IMs. After 1986, the risk of cutaneous SCCs after transplanta-
tion significantly decreased compared with transplantations
in earlier time periods (Table 2).
Factors that characterized the different transplantation
time periods are depicted in Table 3. The most important
differences were increasing age at transplantation in the later
time periods and important differences in immunosuppres-
sive regimens (Table 3).
Patients with cutaneous SCCs are at risk for subsequent IMs
Table 4 shows the distribution of patients without and with
cutaneous SCCs before the development of IMs. Of the KTRs
with IMs 22% had a prior cutaneous SCCs, whereas only 8%
of the patients without IMs had developed cutaneous SCCs
(last row of Table 4). Adjustment for age at transplantation,
sex, time period of transplantation, and immunosuppressive
therapy reduced the hazard ratio from 4 to 3, suggesting that
there was partial confounding by these factors for the
association between cutaneous SCCs and IMs (Table 4).
The analyses stratified for time period of transplantation and
immunosuppressive regimen were always in the same
direction as the analyses on all KTRs together, which can
be used as an argument that the development of cutaneous
SCCs is associated with an increased risk of IMs, largely
independent of period of transplantation and immunosup-
pressive regimen (Table 4). It should be noted, however, that,
although not statistically significant, the hazard ratios for
developing IMs are increasing by transplantation period and
that the hazard ratio is much higher in the KTRs immuno-
suppressed with mycophenolate mofetil (Table 4). The latter
observation may indicate that immunosuppression and
period of transplantation may also be playing a significant
but smaller role. These stratified analyses, however, are
hampered by low numbers of events in some of the strata. For
example, there were only four patients with a prior cutaneous
SCCs in the time period between 1996 and 2006, and only
six patients with a prior cutaneous SCCs among the KTRs
immunosuppressed with mycophenolate mofetil, resulting in
a low statistical power and large confidence intervals
(Table 4). There was no statistically significant interaction
between the immunosuppressives used and cutaneous SCCs.
Compared with the general population, the risk to develop
IMs was 1.6 times increased in all KTRs together (Table 5;
Wisgerhof et al., 2011). In KTRs with prior cutaneous SCCs,
however, the SMR was much higher, and in KTRs without
cutaneous SCCs the SMR was only marginally increased
(Table 5). The 29 IMs that developed in the KTRs with prior
cutaneous SCCs consisted of 3 head and neck cancers (one
oral cavity, one salivary glands, one pharynx), 11 cancers of
the digestive organs (two esophagus, four stomach, four
colon, one biliary tract), 4 lung cancers, 1 breast cancer, 3
prostate cancers, 6 hematolymphopoetic cancers (three
leukemia, three lymphomas), and 1 unknown primary cancer.
DISCUSSION
This study showed a 3-fold increased risk of IMs in KTRs with
a prior cutaneous SCCs. The risk of IMs in KTRs without
cutaneous SCCs was only marginally increased compared
with the general population. The development of cutaneous
SCCs may, therefore, be used as an important indicator of
increased risk of IMs in these patients.
1,906 KTRs were
transplanted
1,800 KTRs were
analyzed
8 Patients lost from
follow-up at the first
transplantation
38 Patients already had
malignancy before
transplantation
49 Patients developed
basal cell carcinoma
without other malignancy
11 Patients developed
other type of skin cancer
(malignant melanoma,
Kaposi′s sarcoma, and so on)
Figure 1. Selection of kidney transplant recipients (KTRs) for this study.
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The 3-fold increased risk of IMs in KTRs with cutaneous
SCCs is compatible with some studies in the general
population, in which a 1.2- to 2.0-fold increased risk of IMs
has been reported in patients with prior cutaneous SCCs (Levi
et al., 1997; Karagas et al., 1998; Wassberg et al., 1999;
Hjalgrim et al., 2000; Hu et al., 2005; Chen et al., 2008;
Krueger and Williams, 2010). An inherited predisposition
of cancer, a suboptimal immune response, a different level
of immunosuppression, or a different immunosuppressive
drug regimen, or lifestyle factors (smoking, sun exposure), are
possible explanations for the increased risk of IMs in patients
with prior cutaneous SCCs (Karagas et al., 1998).
Other studies in the general population, however, have
found no or even a negative association between IMs and
prior cutaneous SCCs (Levi et al., 1997; de Vries et al., 2007;
Grant, 2007; Tuohimaa et al., 2007; Soerjomataram et al.,
2008; Cantwell et al., 2009). A mechanism posited to explain
this phenomenon involves the connection between sun
exposure and vitamin D production in the patients who
develop cutaneous SCCs, and a consequent decreased risk of
Table 1. Baseline characteristics of 1,800 kidney transplant recipients without and with cutaneous SCC or internal
malignancy
No malignancy Cutaneous SCC1 Internal malignancy1
Number of patients: N 1,521 176 142
Time periods of transplantation: N (%)
1966–1975 168 (11.0) 54 (30.7) 22 (15.5)
1976–1985 315 (20.7) 84 (47.7) 51 (35.9)
1986–1995 429 (28.3) 34 (19.3) 54 (38.0)
1996–2006 609 (40.0) 4 (2.3) 15 (10.6)
Immunosuppressive therapy: N (%)
Aza combination 501 (34.8) 135 (76.7) 77 (54.2)
MMF combination 473 (32.8) 7 (4.0) 8 (5.6)
CyA or Tac 467 (32.4) 34 (19.3) 57 (40.2)
Missing values 80 (5.3%) 0 0
Sex: N (%)
Female 586 (38.5) 57 (32.4) 63 (44.4)
Male 935 (61.5) 119 (67.6) 79 (55.6)
Age at transplantation (years)
Median (25–75%) 43.2 (32.4–54.8) 39.1 (28.5–47.3) 46.1 (35.1–53.3)
Age at first cancer (years)
Median (25–75%) — 58.5 (46.1–64.2) 62.3 (51.3–69.6)
Follow-up after transplantation (years)
Median (25–75%) 7.7 (3.2–15.1) 22.4 (15.1–27.9) 13.4 (7.6–19.0)
Timing of malignancies
Only cutaneous SCC — 137 —
SCC before IM — 29 29
IM before SCC — 10 10
Only internal malignancy — — 103
Abbreviations: Aza, azathioprine; CyA, cyclosporine A; IM, internal malignancy; MMF, mycophenolate mofetil; SSC, squamous cell carcinoma;
Tac, tacrolimus.
1The total number of patients is 1,800, but 39 patients have both cutaneous SCC and IMs.
The distributions of these characteristics stratified according to time periods of transplantation are presented in Table 3.
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IMs because of the high vitamin D levels in these patients (de
Vries et al., 2007; Garland et al., 2009; Krueger and
Williams, 2010). However, the reliability of the protective
effect of UV-induced high vitamin D levels has been
questioned by other researchers (Lindelof et al., 2011).
KTRs with cutaneous SCCs visit their dermatologists
usually four times per year and sometimes even more
frequently, which is more often than patients without skin
cancer. These extra visits may lead to some degree of
ascertainment bias, because these KTRs may receive more
tests and scrutiny, which may have resulted in a higher
rate of IM detection. Dermatologists, however, do not
routinely ask for symptoms, which may be related to IMs,
and the development of cutaneous SCCs is no reason for
their nephrologists to increase the number of routine
follow-up visits. It is, therefore, not likely that ascertain-
ment bias explains the increased risk of IM in KTRs with
cutaneous SCCs.
An intriguing finding in our study was the impressive drop
in risk of cutaneous SCCs in the later transplantation time
periods despite the fact that the patients were becoming
increasingly older at transplantation, whereas this drop in risk
was not observed for IMs. At first sight, the changing
immunosuppressive regimen could be responsible for the
drop in cancer risk, as immunosuppression with Aza was
abandoned after 1986. If immunosuppression would have
been the main factor, a similar effect could have been
expected for IMs. The later transplantation time periods are
also characterized by stringent advices regarding sun avoid-
ance. It is conceivable that avoiding sun exposure strongly
decreases the risk of cutaneous SCCs and leaves the risk of IMs
unaffected. Yet another possibility would be a lower detection
rate of cutaneous SCCs during the later time periods. This
option does not appear to be plausible, because almost all
KTRs with skin problems from the studied cohort were
regularly followed up in our specialized dedicated KTR clinic,
Table 2. Risk factors for cutaneous SCC and internal malignancy in 1,800 kidney transplant recipients1
Cutaneous SCC Internal malignancy
Non-adjusted hazard
ratio (95% CI)
Adjusted hazard
ratio (95% CI)2
Non-adjusted hazard
ratio (95% CI)
Adjusted hazard
ratio (95% CI)2
Time periods of transplantation
1966–1975 1 1 1 1
1976–1985 0.95 (0.67; 1.3) 0.76 (0.53; 1.1) 1.4 (0.82; 2.3) 0.99 (0.58; 1.7)
1986–1995 0.59 (0.37; 0.92) 0.38 (0.21; 0.67) 2.0 (1.2; 3.5) 1.2 (0.61; 2.2)
1996–2006 0.23 (0.08; 0.66) 0.13 (0.04; 0.46) 1.3 (0.63; 2.6) 1.1 (0.43; 2.6)
Immunosuppressive therapy
Aza combination 1 1 1 1
MMF combination 0.37 (0.17; 0.81) 0.62 (0.24; 1.6) 0.48 (0.23; 1.0) 0.27 (0.11; 0.66)
CyA or Tac 0.67 (0.45; 0.99) 0.64 (0.39; 1.0) 1.7 (1.1; 2.4) 0.83 (0.51; 1.3)
Sex
Female 1 1 1 1
Male 1.4 (1.0; 2.0) 1.7 (1.2; 2.3) 0.80 (0.57; 1.1) 0.86 (0.62; 1.2)
Age at transplantation (years)
o30 1 1 1 1
30–39 1.5 (1.0; 2.3) 1.9 (1.2; 2.9) 3.0 (1.6; 5.4) 3.0 (1.6; 5.6)
40–49 2.8 (1.8; 4.2) 3.7 (2.4; 5.6) 5.0 (2.8; 8.9) 5.3 (2.9; 9.7)
50–59 2.2 (1.3; 3.9) 4.1 (2.3; 7.3) 7.7 (4.1; 14.3) 7.8 (4.1; 15.0)
X60 5.5 (2.9; 10.4) 15.3 (7.5; 31.2) 12.2 (6.1; 24.5) 12.9 (6.1; 27.3)
Increase of risk per 10 years 1.5 (1.3; 1.7) 1.7 (1.5; 2.0) 1.8 (1.6; 2.1) 1.8 (1.5; 2.1)
Abbreviations: Aza, azathioprine; CI, confidence interval; CyA, cyclosporine A; MMF, mycophenolate mofetil; Tac, tacrolimus.
1The distribution of the different factors is provided in Table 1.
2Hazard ratios are adjusted for sex, age at transplantation (as continuous variable), time period of transplantation, and immunosuppressive therapy.
Statistically significant hazard ratios are indicated in italics.
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dermatologists are currently better trained to recognize this
specific problem in KTRs, nephrologists in the Netherlands are
educated to refer KTRs with skin problems to a dermatologist
at an early stage, and all suspicious lesions were biopsied for a
histological diagnosis.
A limitation of the study is that we do not have complete
data regarding immunosuppressive drug regimens and
switching over time, and that we do not have individualized
data for the use of anti-thymocyte globulin or muromonab-
CD3 (Orthoclone OKT3) in the KTRs who were transplanted
before 1986, and thus we cannot adjust for these potential
confounders. In the KTRs who were transplanted in 1986 and
later, however, there was no association between the use of
anti-thymocyte globulin and/or OKT3 and SCCs (Wisgerhof
et al., 2009), and there was also no association with IMs (data
not shown). It is possible that immunosuppression and year of
transplantation may be playing a significant but smaller role,
and the study was underpowered to detect such a difference.
The observation that KTRs show an increased risk of IMs,
in particular carcinomas of the digestive organs, lungs, and
prostate after the development of cutaneous SCCs, is to our
knowledge previously unreported. Therefore, this association
should be validated in other studies. Both nephrologists and
dermatologists should be aware of the increased risk of IMs in
KTRs with cutaneous SCCs and should be extra careful when
skin cancers start to develop in their patients.
MATERIALS AND METHODS
Patients
We performed a cohort study of all 1,906 patients who received a first
kidney transplantation at the Leiden University Medical Center
(LUMC) between March 1966 and January 2006 (Wisgerhof et al.,
2011). The follow-up of the patients ended arbitrarily on 1 June 2007.
The study adhered to the Declaration of Helsinki Principles, and
the medical ethics committee of the LUMC had approved the
study design.
Collection of data
Data recorded for all KTRs included the date of the first transplanta-
tion, age at transplantation, sex, and the dates of cancer, death, or
last follow-up. The main outcomes of cancer were the diagnoses of
IMs and cutaneous SCCs and were collected from the computerized
oncological registry of the LUMC, the database from the Department
of Pathology and the National Histological Database (PALGA;
Table 3. Distribution of risk factors during different time periods of transplantation
1966–1975 1976–1985 1986–1995 1996–2006
Number of patients: N 234 433 506 627
Immunosuppressive therapy: N (%)
Aza combination 230 (98.3) 365 (84.3) 88 (17.4) 1 (0.2)
MMF combination 1 (0.4) 2 (0.5) 59 (11.7) 425 (77.6)
CyA or Tac 3 (1.3) 66 (15.2) 358 (70.9) 122 (22.2)
Missing values 0 0 1 (0.2%) 79 (12.6%)
Sex: N (%)
Female 82 (35.0) 180 (41.6) 184 (36.4) 246 (39.2)
Male 152 (65.0) 253 (58.4) 322 (63.6) 381 (60.8)
Age at transplantation (years)
Median (25–75%) 31.6 (22.5–41.9) 36.6 (26.7–46.9) 46.5 (36.9–56.9) 50.1 (38.6–59.1)
Age at first cutaneous SCC (years) N=54 N=84 N=34 N=4
Median (25–75%) 46.8 (42.1–56.3) 53.4 (46.6–58.6) 60.1 (54.2–65.4) 68.4 (64.9–69.4)
Age at first internal malignancy (years) N=22 N=51 N=54 N=15
Median (25–75%) 54.3 (44.4–61.9) 56.5 (43.9–62.4) 57.8 (53.2–66.7) 60.5 (49.7–71.6)
Follow-up after transplantation (years)
Median (25–75%) 19.2 (6.2–31.9) 18.5 (10.0–24.4) 12.3 (6.3–15.6) 4.2 (2.1–7.0)
Abbreviations: Aza, azathioprine; CyA, cyclosporine A; MMF, mycophenolate mofetil; SCC, squamous cell carcinoma; Tac, tacrolimus.
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Wisgerhof et al., 2011). The medical charts were also hand searched
for the diagnosis of cancer. Premalignant lesions and in situ
carcinomas were not included. KTRs who were lost to follow-up at
the first transplantation, who already had cancer before the first
transplantation, and patients with cutaneous basal cell carcinoma or
other types of skin cancer (malignant melanoma, Kaposi’s sarcoma,
sweat gland carcinoma, and so on) without cutaneous SCCs or IMs
were excluded from all analyses (Figure 1).
Table 4. Risk of internal malignancy in patients with prior cutaneous squamous cell carcinoma
Time period of transplantation
immunosuppressive regimen
No internal
malignancy
Internal
malignancy
Non-adjusted
hazard ratio (95% CI)
Adjusted hazard
ratio (95% CI)1
1966–1975
Squamous cell carcinoma: N (%)
No 168 (79.2) 12 (66.7) 1 1
Yes 44 (20.8) 6 (33.3) (4)2 2.9 (1.1; 7.9) 1.9 (0.67; 5.2)
1976–1985
Squamous cell carcinoma: N (%)
No 315 (82.5) 34 (70.8) 1 1
Yes 67 (17.5) 14 (29.2) (3)2 4.1 (2.0; 8.1) 2.8 (1.4; 5.6)
1986–1995
Squamous cell carcinoma: N (%)
No 429 (94.9) 43 (84.3) 1 1
Yes 23 (5.1) 8 (15.7) (3)2 6.1 (2.8; 13.4) 4.1 (1.9; 9.1)
1996–2006
Squamous cell carcinoma: N (%)
No 609 (99.5) 14 (93.3) 1 1
Yes 3 (0.5) 1 (6.7) (0)2 10.9 (1.3; 90.2) 6.5 (0.70; 60.4)
Azathioprine combination
Squamous cell carcinoma: N (%)
No 501 (82.5) 48 (68.6) 1 1
Yes 106 (17.5) 22 (31.4) (7)2 4.6 (2.7; 8.1) 3.0 (1.7; 5.2)
Mycophenolate mofetil combination
Squamous cell carcinoma: N (%)
No 473 (98.7) 7 (87.5) 1 1
Yes 6 (1.3) 1 (12.5) (0)2 69.0 (6.0; 786.0) 37.1 (2.6; 543.5)
Cyclosporine and tacrolimus combination
Squamous cell carcinoma: N (%)
No 467 (94.9) 48 (88.9) 1 1
Yes 25 (5.1) 6 (11.1) (3)2 2.7 (1.1; 6.7) 2.1 (0.88; 5.2)
All patients together
Squamous cell carcinoma: N (%)
No 1,521 (91.7) 103 (78.0) 1 1
Yes 137 (8.3) 29 (22.0) (10)2 4.3 (2.7; 6.8) 3.0 (1.9; 4.7)
1The hazard ratio for all patients together was adjusted for sex, age at transplantation, time period of transplantation, and immunosuppressive therapy.
The hazard ratios in the different strata of time after transplantation and immunosuppressive regimen were adjusted for age and sex.
2Number of patients who were censored because the event (internal malignancy) occurred before the development of cutaneous squamous cell carcinoma.
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The diagnoses of IMs were based on the International Classifica-
tion of Diseases 10th Modification Diagnoses Codes (ICD-10).
Different from the ICD-10 classification, we classified lip carcinomas
as cutaneous SCCs and not as IMs.
Statistical data for cancer per 5-year age categories were obtained
from the Eindhoven Cancer Registry for the period 1966–1988 and
from the Netherlands Cancer Registry for the period 1989–2006 as
described before (Wisgerhof et al., 2011). The time period of
transplantation was arbitrarily stratified into 1966–1975; 1976–1985;
1986–1995; and 1996–2006.
Immunosuppressive regimens
Between 1966 and 1986, the immunosuppressive treatment of KTRs
in our clinic consisted of duo therapy with prednisolone and Aza, but
shortly after 1986 all new KTRs were immunosuppressed with
prednisolone and CyA. From the mid 90s, most KTRs were treated
with prednisolone, mycophenolate mofetil (MMF), and CyA, and
later with prednisolone, MMF, and tacrolimus. The initial and
maintenance immunosuppressive therapies were categorized into
three basic treatment groups: duo or triple therapy with Aza in any
combination, duo or triple therapy with MMF in any combination,
and duo therapy without Aza or MMF (that is, a combination
of prednisolone with CyA or prednisolone with tacrolimus). If
no data were available for maintenance immunosuppressive therapy,
the data of the initial immunosuppressive therapy were used.
For all our analyses with immunosuppressive therapy, we used
the subcategorization of maintenance therapy because the patients
were, generally, exposed to this regimen for the most prolonged
period of time.
KTRs, in whom acute graft rejections were observed, were
generally initially treated with methylprednisolone. When this
therapy was not sufficient to prevent further rejection, a second
rejection treatment with anti-thymocyte globulin and a third
rejection treatment again with methylprednisolone were given. In
exceptional cases, muromonab-CD3 (Orthoclone OKT3) was given
when a fourth rejection treatment was needed. With the exception
of some rare patients, induction treatments with anti-thymocyte
globulin and/or OKT3 were not given to KTRs who were
transplanted in the LUMC between 1966 and 1995.
Statistical analyses
For statistical analyses, we used w2 tests for categorical variables and
Student’s t-tests for continuous variables. Cox proportional hazard
analyses were used to calculate hazard ratios for the development of
IMs or cutaneous SCCs and to adjust for potentially confounding
factors. As potential confounding factors, we selected age at
transplantation and sex, because these factors have been reported to
be associated with both IMs and cutaneous SCCs. The time period of
transplantation and the immunosuppressive therapy were also selected
as potential confounding factors, because these factors also appeared
to be associated with IMs or cutaneous SCCs.
In traditional Cox regression analysis, a risk factor measured at
baseline is related to the event thereafter. During follow-up, however,
things may change: either the effect of a fixed baseline risk factor
may vary over time, resulting in a weakening or strengthening of
associations over time, or the risk factor itself may vary over time.
The development of cutaneous SCCs, when using IMs as the outcome,
is an example of the latter. Time-dependent Cox regression analyses
were used to measure the effect of this so-called time-dependent risk
factor. As opening dates for the analyses, we used the date of the first
transplantation; as closing dates we used the date of diagnosis of the
IM, the date of the patient’s death, or the date of last follow-up.
Patients were not censored from the analyses at graft failure.
The incidence of IMs in the KTRs after transplantation was
compared with the incidence in the general population, the data for
which were obtained from the Eindhoven Cancer Registry and the
Netherlands Cancer Registry by calculating the SMR with 95%
confidence interval and was matched for age, sex, and time period in
which the malignancy had occurred (Wisgerhof et al., 2011).
P-values below 0.05 were considered significant. All statistical
calculations were performed using SPSS for Windows version 17
(SPSS, Chicago, IL).
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